



East London
NHS Foundation Trust

Information Governance

The Green
1 Roger Dowley Court
Russia Lane
London
E2 9NJ

Email elft.foi@nhs.net

Website: <https://www.elft.nhs.uk>

7th April 2022

Our reference: FOI DA4163

I am responding to your request for information received **1st April**. This has been treated as a request under the Freedom of Information Act 2000.

I am now enclosing a response which is attached to the end of this letter. Please do not hesitate to contact me on the contact details above if you have any further queries.

Yours sincerely,

Lara Cousens
Information Governance Manager – Information Rights

If you are dissatisfied with the Trust's response to your FOIA request then you should contact us and we will arrange for an internal review of this decision.

If you remain dissatisfied with the decision following our response to your complaint, you may write to the Information Commissioner for a decision under Section 50 of the Freedom of Information Act 2000. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Tel: 0303 123 1113
Web: www.ico.org.uk

Please note that the data supplied is not allowed to be re-used and/or published without the explicit consent of East London NHS Foundation Trust. Please contact the signatory to request permission if this is your intention

Chair: Eileen Taylor (Interim)

Chief Executive: Paul Calaminus

We care

We respect

We are inclusive

Request:

Question 1: In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- **Abemaciclib (Verzenios) + aromatase inhibitor ***
- **Abemaciclib (Verzenios) + Fulvestrant (Faslodex)**
- **Alpelisib (Piqray) + Fulvestrant (Faslodex)**
- **Atezolizumab (Tecentriq)****
- **Bevacizumab (Avastin)**
- **Eribulin (Halaven)**
- **Everolimus (Afinitor) + Exemestane**
- **Fulvestrant (Faslodex) as a single agent**
- **Gemcitabine + paclitaxel**
- **Herceptin (Trastuzumab) + paclitaxel**
- **Herceptin (Trastuzumab) as a single agent**
- **Lapatinib (Tyverb)**
- **Neratinib (Nerlynx)**
- **Olaparib (Lynparza)**
- **Palbociclib (Ibrance) + aromatase inhibitor***
- **Palbociclib (Ibrance) + Fulvestrant (Faslodex)**
- **Pertuzumab (Perjeta) + trastuzumab + docetaxel**
- **Ribociclib (Kisqali) + aromatase inhibitor***
- **Ribociclib (Kisqali) + Fulvestrant (Faslodex)**
- **Talazoparib (Talzenna)**
- **Trastuzumab emtansine (Kadcyla)**
- **Other active systemic anti-cancer therapy ****

***aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

****eg. docetaxel, vinorelbine or capecitabine as a single agent**

Question 2: For the above patients, how many of these received their first ever dose for each product line?

Answer: Section 1(1) of the Freedom of Information Act 2000 states:

Any person making a request for information to a public authority is entitled—

- (a) to be informed in writing by the public authority whether it holds information of the description specified in the request, and
- (b) if that is the case, to have that information communicated to him.

East London NHS Foundation Trust is a mental and community health trust and does not provide treatment in relation to the above questions 1 – 2. Therefore the Trust is unable to disclose this information.